Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Diabetes Care

Topics

Chemistry

Pathology

Medicine

Internal Medicine

Endocrinology

Show all topics

DOI

10.2337/dc13-2105

License

CC-BY-NC-ND

Other Formats

PDF